Longevity Evidence Lab Human evidence, uncertainty intact
Research interpretation, not diagnosis or personal treatment advice. Urgent symptoms belong with a clinician, not a browser tab.
Home / Compare
Side-by-side evidence

Compare interventions

Use the same six evidence dimensions for both. This prevents a strong animal result for one product being compared with a human clinical result for another.

versus
NAD+ precursor

Nicotinamide riboside (NR)

Early human evidence

Biologically active and well studied for NAD elevation; clinical outcome evidence is thin.

Human clinical outcomes Preliminary
Human biomarkers Strong
Animal lifespan Limited
Mechanistic plausibility Moderate
Safety certainty Limited
Direct longevity relevance Preliminary

Verdict: NR reliably alters NAD metabolism in many human studies, but biomarker movement has not translated into a consistent package of functional or disease benefits. It should be viewed as an active NAD precursor under clinical investigation rather than established longevity therapy.

Open full dossier
NAD+ precursor

NMN

Early human evidence

Raises NAD-related biomarkers; broad healthspan benefits have not followed reliably.

Human clinical outcomes Preliminary
Human biomarkers Moderate
Animal lifespan Limited
Mechanistic plausibility Moderate
Safety certainty Limited
Direct longevity relevance Preliminary

Verdict: Nicotinamide mononucleotide can raise NAD-related measures in humans, which confirms biological activity. Trials have reported selected metabolic or functional effects, but results are mixed, studies are generally short, and no human evidence shows slower ageing or longer life.

Open full dossier